Foghorn Therapeutics (FHTX) Operating Leases: 2020-2025
Historic Operating Leases for Foghorn Therapeutics (FHTX) over the last 5 years, with Sep 2025 value amounting to $22.5 million.
- Foghorn Therapeutics' Operating Leases fell 25.65% to $22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.5 million, marking a year-over-year decrease of 25.65%. This contributed to the annual value of $28.1 million for FY2024, which is 37.74% down from last year.
- As of Q3 2025, Foghorn Therapeutics' Operating Leases stood at $22.5 million, which was down 4.93% from $23.7 million recorded in Q2 2025.
- Foghorn Therapeutics' 5-year Operating Leases high stood at $62.3 million for Q1 2021, and its period low was $22.5 million during Q3 2025.
- Over the past 3 years, Foghorn Therapeutics' median Operating Leases value was $30.3 million (recorded in 2024), while the average stood at $32.8 million.
- As far as peak fluctuations go, Foghorn Therapeutics' Operating Leases grew by 6.98% in 2021, and later tumbled by 37.74% in 2024.
- Over the past 5 years, Foghorn Therapeutics' Operating Leases (Quarterly) stood at $58.3 million in 2021, then decreased by 11.70% to $51.5 million in 2022, then dropped by 12.49% to $45.1 million in 2023, then plummeted by 37.74% to $28.1 million in 2024, then decreased by 25.65% to $22.5 million in 2025.
- Its Operating Leases was $22.5 million in Q3 2025, compared to $23.7 million in Q2 2025 and $25.7 million in Q1 2025.